ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer’s Disease and ALS at American Academy of Neurology Annual Meeting

Apr 24, 2023 ProMIS Neurosciences Inc.   [PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Massachusetts – April 24, 2023 – ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the…
Read More

About The Author

Jonathan Jeriah

See author's posts